icon-    folder.gif   Conference Reports for NATAP  
 
  Conference on Retroviruses
and Opportunistic Infections
Boston USA
March 8-11, 2020
Back grey_arrow_rt.gif
 
 
 
CROI ART/HIV Drug Studies
 
 
  Cabotegravir + rilpivirine every 2 months is noninferior to monthly: ATLAS-2M study Every-2-Month Maintenance CAB + RPV Noninferior to Monthly Dosing for 48 Weeks - (03/09/20)
 
Potential Drugs for Multi-drug Resistant HIV NOVEL ANTIRETROVIRAL AGENTS: TRANSFORMING THE CARE OF PEOPLE WITH HIV - (03/11/20)
 
Preexisting Resistance and B/F/TAF Switch Efficacy in African Americans (03/13/20)
 
RANDOMIZED SWITCH TO B/F/TAF IN AFRICAN AMERICAN ADULTS WITH HIV - (03/12/20)
 
144-Week Efficacy and Safety of B/F/TAF in Treatment-Naive Adults Age ≥50 Years - (03/12/20)
 
DTG + 3TC VS DTG + TDF/FTC (GEMINI-1 & -2): CONFIRMED VIROLOGIC WITHDRAWALS THROUGH WEEK 96 - (03/11/20)
 
LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR HIV TREATMENT: FLAIR WEEK 96 RESULTS - (03/11/20)
 
Use of D/C/F/TAF With Neurologic/Psychiatric Comorbidities: AMBER Subgroup Analysis (03/16/20)
 
Risks of metabolic syndrome, diabetes, and cardiovascular disease in ADVANCE trial.
Predicted Rise in Diabetes Risk With TAF/FTC+DTG Versus TDF/FTC+DTG- (03/12/20)
 
FOSTEMSAVIR EXPOSURE-RESPONSE RELATIONSHIPS IN TREATMENT EXPERIENCED HIV PATIENTS (03/16/20)
 
CABOTEGRAVIR AND RILPIVIRINE PK FOLLOWING LONG-ACTING HIV TREATMENT DISCONTINUATION (03/16/20)
 
DOSE-RESPONSE RELATIONSHIP OF SUBCUTANEOUS LONG-ACTING HIV CAPSID INHIBITOR GS-6207 (03/16/20)
 
ABSENCE OF GS-6207 PHENOTYPIC RESISTANCE IN HIV Gag CLEAVAGE SITE AND OTHER MUTANTS (03/16/20)
 
PK, Food Effect, and Safety of Oral GS-6207, a Novel HIV-1 Capsid Inhibitor (03/16/20)
 
Islatravir Metabolic Outcomes in a Phase 2b Trial of Treatment-Naïve Adults with HIV-1 - (03/09/20)
 
75 CROI NATAP Reports
Conference on Retroviruses and Opportunistic Infections
Boston USA
March 8-11, 2020